ホーム › 膀胱癌 › オハイオ

オハイオにおける膀胱癌の臨床試験

オハイオ内の拠点で、膀胱癌に関する36件の研究が参加者を募集しています。

オハイオ内の都市

公式研究テキスト（英語）

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Cleveland Clinic Taussig Cancer Center, Cleveland
Ohio State University Comprehensive Cancer Center, Columbus

被験者募集中第2相

18歳以上 · 全性別 · 2026/10/01更新 · NCT06263153

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
MetroHealth Medical Center, Cleveland
Ohio State University Comprehensive Cancer Center, Columbus
他1件

被験者募集中第2相

18歳以上 · 全性別 · 2026/10/01更新 · NCT07061964

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

TriState Urologic Services PSC Inc. dba The Urology Group ( Site 0122), Cincinnati

被験者募集中第2相

18歳以上 · 全性別 · 2026/10/01更新 · NCT06833073

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Strecker Cancer Center-Belpre, Belpre
Adena Regional Medical Center, Chillicothe
Ohio State University Comprehensive Cancer Center, Columbus
他22件

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/30更新 · NCT03866382

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Oncology Hematology Care Clinical Trials, LLC, Fairfield

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/30更新 · NCT07566156

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Riverside Methodist Hospital, Columbus
Grant Medical Center, Columbus
Doctors Hospital, Columbus
他3件

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/30更新 · NCT06770582

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

University Hospitals Cleveland Medical Center, Cleveland
Cleveland Clinic Foundation, Cleveland
Cleveland Clinic Taussig Cancer Center Investigational Pharmacy, Cleveland

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/28更新 · NCT07421700

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0822), Cincinnati

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT07419295

DESTINY-PANTUMOUR04

Research Site, Canton
Research Site, Maumee

被験者募集中観察研究

18歳〜130歳 · 全性別 · 2026/09/25更新 · NCT07124000

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

University of Cincinnati Medical Center, Cincinnati
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/22更新 · NCT07218380

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Ohio State University, Columbus

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/21更新 · NCT06529822

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

University Hospitals Cleveland Medical Center, Cleveland

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/15更新 · NCT07217171

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Cleveland Clinic, Cleveland
Toledo Clinic Cancer Center, Toledo

被験者募集中観察研究

18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

University Hospitals Cleveland Medical Center, Cleveland

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/04更新 · NCT06465069

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Cleveland Clinic - Oncology Department, Cleveland

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/03更新 · NCT06760819

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

The Urology Group (Solaris), Cincinnati
University of Cincinnati Cancer Center, Cincinnati
Cleveland Clinic, Cleveland
他2件

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/03更新 · NCT06567743

The Vanguard Study: Testing a New Way to Screen for Cancer

Louis Stokes Cleveland VA Medical Center, Cleveland

被験者募集中健康なボランティア歓迎

45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Summa Health System - Akron Campus, Akron
Cleveland Clinic Akron General, Akron
Summa Health System - Barberton Campus, Barberton
他44件

被験者募集中観察研究健康なボランティア歓迎

40歳〜75歳 · 全性別 · 2026/09/02更新 · NCT05334069

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

Cleveland Clinic Taussig Cancer ( Site 5036), Cleveland

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/01更新 · NCT07232602

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Cleveland Clinic Main Campus, Cleveland, Cleveland

被験者募集中第2相

18歳以上 · 全性別 · 2026/08/24更新 · NCT05951179

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

University of Cincinnati Medical Center (UCMC), Cincinnati
The Ohio State University (OSU), Columbus

被験者募集中第1相

18歳以上 · 全性別 · 2026/08/20更新 · NCT05614739

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

UH Seidman Cancer Center at UH Avon Health Center, Avon
UHHS-Chagrin Highlands Medical Center, Beachwood
Case Western Reserve University, Cleveland
他2件

被験者募集中第3相

18歳以上 · 全性別 · 2026/08/18更新 · NCT07097142

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

The Ohio State University Comprehensive Cancer Center, Columbus

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

University of Cincinnati Medical Center, Cincinnati
Central Ohio Urology Group, Gahanna
Clinical Research Solutions - Helios Clinical Research, Middleburg Heights

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/08/07更新 · NCT04752722

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Ohio State University Comprehensive Cancer Center, Columbus

被験者募集中第3相

18歳以上 · 全性別 · 2026/08/05更新 · NCT07000084

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

The Ohio State University, Columbus

被験者募集中観察研究

18歳以上 · 全性別 · 2026/07/31更新 · NCT07225127

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Fairview Hospital, Cleveland
Cleveland Clinic, Cleveland
The James Outpatient Care West Campus, Columbus
他1件

被験者募集中第2/3相

18歳以上 · 全性別 · 2026/07/29更新 · NCT07106762

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Nationwide Children's Hospital, Colombus
The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Taylor Cancer Research Center, Maumee

被験者募集中第2相

8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797